k Risankizumab humanised monoclonal antibody Patient holding a prefilled pen of Risankizumab medication. Marketed as Skyrizi, Risankizumab is a humanised monoclonal antibody that binds to interleukin 23A IL23A and blocks the activity of proinflammatory cytokines. Risankizumab is used to treat moderate to severe plaque psoriasis and active psoriatic arthritis. It is administered by a subcutaneous injection., by DR P. MARAZZISCIENCE PHOTO LIBRARY Stock Photo - Afloimages
Sign up
Login
All images
Risankizumab humanised monoclonal antibody Patient holding a pre filled pen of Risankizumab medication. Marketed as Skyrizi, Risankizumab is a humanised monoclonal antibody that binds to interleukin 23A IL 23A and blocks the activity of pro inflammatory cytokines. Risankizumab is used to treat moderate to severe plaque psoriasis and active psoriatic arthritis. It is administered by a subcutaneous injection., by DR P. MARAZZI SCIENCE PHOTO LIBRARY
RM
Add to Lightbox
Download Comp

Risankizumab humanised monoclonal antibody

Patient holding a pre-filled pen of Risankizumab medication. Marketed as Skyrizi, Risankizumab is a humanised monoclonal antibody that binds to interleukin 23A (IL-23A) and blocks the activity of pro-inflammatory cytokines. Risankizumab is used to treat moderate to severe plaque psoriasis and active psoriatic arthritis. It is administered by a subcutaneous injection., by DR P. MARAZZI/SCIENCE PHOTO LIBRARY

Details

ID
185191008

Collection

License type
Rights Managed

Photographer

Model Release
Model release is available



More
Top Categories
Editorial
2024 Paris Olympics
Latest News
Latest Sport
Latest Entertainment
2020 Tokyo Olympics
Creative
People and Lifestyle
Sport and Leisure
Business and Technology
Landscape
Animals
Videos
Sport and Leisure
Drone and Timelapse
People and Lifestyle
Business and Technology
Landscape
Sign in
Register
Member access
Login not found.
Forgot Your Password?